Syon Capital LLC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 22,814 shares of the company's stock, valued at approximately $270,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ROIV. Barclays PLC increased its holdings in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after buying an additional 75,609 shares during the last quarter. Virtu Financial LLC bought a new stake in Roivant Sciences in the third quarter worth approximately $207,000. Te Ahumairangi Investment Management Ltd increased its stake in shares of Roivant Sciences by 19.9% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock worth $2,313,000 after purchasing an additional 33,467 shares during the last quarter. Tyro Capital Management LLC raised its holdings in shares of Roivant Sciences by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock valued at $20,252,000 after purchasing an additional 10,649 shares in the last quarter. Finally, Retirement Systems of Alabama raised its holdings in shares of Roivant Sciences by 26.9% during the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock valued at $6,116,000 after purchasing an additional 112,286 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Roivant Sciences
In related news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,116,345 shares in the company, valued at approximately $11,409,045.90. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,395,541 shares of company stock valued at $14,922,538 in the last quarter. Corporate insiders own 7.90% of the company's stock.
Roivant Sciences Stock Up 1.6 %
NASDAQ ROIV traded up $0.18 during trading on Monday, hitting $11.19. The company's stock had a trading volume of 8,301,459 shares, compared to its average volume of 5,473,407. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The firm has a market cap of $7.98 billion, a P/E ratio of -74.60 and a beta of 1.25. The firm has a 50 day moving average price of $10.35 and a 200 day moving average price of $11.14.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Wall Street Analysts Forecast Growth
ROIV has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Get Our Latest Stock Report on Roivant Sciences
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
